Will the US ban Western pharma M&A with Chinese biotech by 6 Oct 2026?
Posted 2026-09-23, stated before the outcome.
The US government regulates cross-border mergers and acquisitions to address national security and economic concerns. Pharmaceutical and biotechnology sectors are frequently subject to scrutiny regarding foreign ownership and technology transfer. Industry stakeholders often lobby to influence the scope and timing of such regulatory actions.
The claim
The Trump administration will not issue a broad executive order or new rule within 14 days prohibiting Western pharmaceutical companies from completing mergers and acquisitions with Chinese biotech firms, despite industry lobbying.
The full dossier behind this prediction — the evidence trail, the risk analysis, the monetization scenarios — is available on request: [email protected].
Probabilities are calibrated against the system's own resolved history; after the deadline the outcome is resolved and audited — including the calls we get wrong. Nothing on this page is investment advice.